The following Life Sciences practice note Produced in partnership with Vincenzo Salvatore of BonelliErede provides comprehensive and up to date legal information covering:
In recent years, we have witnessed a constantly growing interest from all stakeholders (the general public, patients associations, physicians, pharmaceutical industry and academia alike) to get access to information concerning medicinal products. Under this pressure, both legislators and medicines regulatory authorities have moved towards a more generous approach giving access to a larger set of documents and information related to the quality, safety and efficacy of medicinal products than ever before. In the EU, the European Medicines Agency (EMA) is the regulatory body responsible for the protection and promotion of human and animal health. Some of the EMA’s key responsibilities include the scientific evaluation of applications for marketing authorisation (MA) of medicines through the centralised procedure and the co-ordination of the EU pharmacovigilance system for the monitoring of the safety of medicinal products. The EMA therefore holds a large volume of scientific and clinical data on medicines. There are several channels through which documents and information on medicinal products can be accessed. These can broadly be summarised as the following:
via a request for access to certain documents to the regulatory authority that hold those documents
following a release pursuant to legal obligations, eg the rules governing clinical trials which mandate that certain information be made publicly available via the clinical trial database or the rules on authorisation of medicines which mandates that public
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
Community order requirementsCommunity order requirements are set out in the Criminal Justice Act 2003 (CJA 2003), as amended by the Legal Aid, Sentencing and Punishment of Offenders Act 2012 (LASPO 2012) and the Offender Rehabilitation Act 2014 (ORA 2014). Criminal Justice Act 2003, s 152(2)
The principles of the notarial act are that it is:•an act of the notary and not of the parties named in the document•a record of a fact, event or transaction•in the form of a document, notwithstanding the form of the underlying document, fact, event or transactionThe purpose of the notarial act is
What is QOCS?Qualified one-way costs shifting (QOCS) was introduced on 1 April 2013 as part of the Jackson costs reforms following the removal of a claimant’s right to recover additional liabilities from the defendant, ie success fees and after the event (ATE) insurance premiums. The relevant CPR
Background to the Single RulebookHistorically, the European Commission (Commission) favours using Directives (rather than Regulations) to set out its legislation in respect of the financial services sector. However, Directives, allowing Member States greater flexibility in how they implement
0330 161 1234
To view our latest legal guidance content,sign-in to Lexis®PSL or register for a free trial.